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A B S T R A C TObjective: Reduced mortality with low-dose computed tomography
(LDCT) lung cancer screening was demonstrated in a large random-
ized controlled study of high-risk individuals. Cost-effectiveness
must be assessed before routine LDCT screening is considered. We
aimed to evaluate the cost-effectiveness of LDCT lung cancer
screening in Israel. Methods: A decision analytic framework was
used to evaluate the decision to screen or not screen from the
health system perspective. The screening arm included 842
moderate-to-heavy smokers aged 45 years or older, screened at
Hadassah-Hebrew University Medical Center from 1998 to 2004. In
the usual-care arm, stage distribution and stage-speciﬁc life expect-
ancy were obtained from the Israel National Cancer Registry data
for 1994 to 2006. Lifetime stage-speciﬁc costs were estimated from
medical records of patients diagnosed and treated at Hadassah
Medical Center in the period 2003 to 2004. The analysis consideredsee front matter Copyright & 2013, International S
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s now afﬁliated with the Department of Oncologypossible biases—lead time, overdiagnosis, and self-selection. Cost
per quality-adjusted-life-year (QALY) gained by screening was
estimated. Results: Base-case incremental cost per QALY gained
was $1464 (2011 prices). Extensive sensitivity analysis afﬁrmed the
low cost per QALY gained. The cost per QALY gained is lower than
$10,000 with probability 0.937 and is lower than $20,000 with
probability 0.978. Conclusions: Our analysis suggests that baseline
LDCT lung cancer screening in Israel presents a good value for the
money and should be considered for inclusion in the National List
of Health Services ﬁnanced publicly.
Keywords: cost per QALY, Israel, low-dose computed tomography, lung
cancer.
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Lung cancer is the leading cause of cancer-related death. In 2008,
there were 1897 individuals diagnosed with lung cancer in Israel
and 1561 deaths in a population of about 7.4 million [1,2]. Lung
cancer rates in Israel are lower than in other Western countries;
the per capita incidence of lung cancer is only approximately one
third of the incidence in the United States. The high fatality rate
of more than 80% and poor 5-year survival rate of only 15%,
however, are similar [3].
Lung cancer diagnosed at an early stage, typically in asymp-
tomatic individuals, can usually be treated by surgical resection,
but in our low-prevalence population, as elsewhere, patients
typically present with symptoms, by which time the disease is
often advanced and inoperable [4].
Screening for cancer is deﬁned as the pursuit of an early
diagnosis of cancer, before symptoms occur, to provide treatment
early, when it is most effective. Early diagnosis can potentiallylead to a signiﬁcant decrease in disease-speciﬁc mortality [5].
Screening strategies are usually applied when the population at
risk is clearly deﬁned. The attributes that make lung cancer
suitable for screening are well known, and include measurable
risk factors, a high mortality rate, differential survival by stage of
disease, a naturally low rate of early detection due to lack of
symptoms in early disease, availability of effective intervention
for early disease, lack of effective therapy in advanced stages of
disease, and the high cost of treatment for advanced disease,
both monetarily and in terms of quality of life [6].
Technological advances in the last two decades led to the
introduction of lung cancer screening with low-dose computed
tomography (LDCT), currently the most promising screening
technique [4]. Compared with chest x-ray, LDCT detects approx-
imately six times as many early lung cancers [7]. In a large
collaborative study, 31,567 asymptomatic individuals at risk for
lung cancer were screened by using LDCT. Lung cancer was
diagnosed in 484 participants, of whom 85% had clinical stage Iociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 2 2 – 9 3 1 923cancer. The estimated 10-year survival rate in this subgroup was
88% overall, and 92% when surgical resection was performed
within 1 month of diagnosis [8].
Recently published results from the National Cancer Institute–
sponsored National Lung Screening Trial showed a reduction in
mortality with LDCT lung cancer screening [9]. The trial com-
pared mortality in a study population of more than 53,000 current
and former heavy smokers aged 55 to 74 years who were
randomized to LDCT or standard chest x-ray lung cancer screen-
ing arms. There were 20% fewer lung cancer deaths in individuals
screened with LDCT [9].
LDCT screening for lung cancer appears to be clinically
effective; however, the cost-effectiveness of screening will ulti-
mately determine health policy decision making. Earlier cost-
effectiveness analyses conducted in North America and Australia
have reached conﬂicting conclusions, partly because of different
approaches for the estimation of effectiveness, and partly
because of different assumptions [6,10–17]. Moreover, it is difﬁ-
cult to generalize results from one study to other settings because
of variability in disease prevalence and in the costs associated
with diagnosis and management, as well as differences in the
ﬁnancial organization of health care systems.
In the current study, we aimed to assess the cost-
effectiveness of screening versus usual care (i.e., the care pro-
vided once a diagnosis following symptoms has been made) for
lung cancer in Israel, from the health care system perspective.Methods
We used a decision analytic framework to evaluate whether to
screen or not screen. The decision tree with its parameters isFig. 1 – Decision tree for LDCT lung cancer screening. LDCT, low
year.presented in Figure 1. The tree represents the sequence of events
in each of the two possible branches—to screen or wait for a
symptomatic diagnosis followed by usual care (the legend for the
parameters symbols is given in Table 2). We note that because
there is no practical observational way to conﬁrm false-negative
cases, this option is disregarded, and all negative results are
considered true negative (“well”).
Incremental survival beneﬁts and costs of baseline screening
for lung cancer are derived from the shift in the stage of disease at
detection. We compared the actual stage distribution found in a
cohort of asymptomatic individuals with lung cancer detected at
LDCT screening with the stage at diagnosis in a group of patients
detected symptomatically in Israel, and compared the lifetime cost
of care for patients with screen-detected and symptom-detected
disease (usual care). This method provides an estimated cost per
quality-adjusted life-year (QALY) gained by screening.
The validity of this method crucially depends on the similarity
between asymptomatic screen-detected and symptomatic patients,
or on accounting for dissimilarity between these groups. In partic-
ular, three sources of concern have been identiﬁed: differences
between the groups in mean age at detection (lead-time bias), the
rate of positive screen detections that will not become symptomatic
(overdiagnosis bias), and possible variance in expected risk between
the screened and symptomatic populations (self-selection bias)
[18,19]. We considered each of these potential biases in our analysis.Data
LDCT screening cohort
Between September 1998 and July 2004, 842 asymptomatic indi-
viduals participated in the LDCT lung cancer screening program at-dose computed tomography; QALY, quality-adjusted life-
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571 participants aged 50 years and older with a smoking history of
more than 10 pack-years were screened. From July 2000 to July
2004, an additional 271 individuals aged 40 years and older with
any smoking history participated in the program [3]. Because of
the relatively small numbers, we considered the two subgroups as
one cohort. Unfortunately, subpopulation analysis based on smok-
ing history, gender, or age was not feasible in this study popula-
tion. Because differences in subpopulations could affect disease
prevalence, overdiagnosis, or self-selection, we have considered
changes in these assumptions in the sensitivity analysis,
discussed below.
The LDCT screening cohort as a whole included 480 men (57%)
and 362 women (43%), with a median of 37 pack-years (moderate-
to-heavy smokers). Median age was 58 years. Because 97% of
cohort members were 45 years or older, we used a proﬁle of the
Israeli population aged 45 years and older for comparison. The
median age of this group in 2004 was 60 years. The screened
population was thus 2 years younger than the corresponding
general population. Further details on the screening outcomes
are reported elsewhere [3].
The diagnostic workup in individuals with positive ﬁndings,
including surveillance frequency as well as duration of follow-up,
was guided by the International Early Lung Cancer Program
enrollment and screening protocol [20].Stage at diagnosis in the usual care arm
National Cancer Registry (NCR) records for 2906 patients diag-
nosed with non–small cell lung cancer (NSCLC) in Israel from
1994 to 2006 were used for estimating stage at diagnosis in the
usual care cohort. NCR staging is based on the Middle East Cancer
Consortium (MECC) classiﬁcation. To match NCR data with the
Tumor-Node-Metastases (TNM) classiﬁcation system, two oncol-
ogists specialized in the treatment of lung cancer (O.G. and M.G.)
considered MECC I comparable to TNM I, MECC II comparable to
TNM II-III, and MECC III analogous to TNM IV. For 58% of the
cases listed in the NCR, the stage at diagnosis was unknown. Our
model considered data on stage at diagnosis for the remaining
1221 patients (42%) in the NCR. The median age at diagnosis for
these patients was 67 years, and 71% were men.Stage-speciﬁc costs and lifetime costs by stage at diagnosis
Cost of care by stage at diagnosis was estimated on the basis of a
review of medical records for 146 patients diagnosed with NSCLC
in the period 2003 to 2004, and treated at our medical center.
Their median age at diagnosis was 67 years, and 61% were men.
Stage-speciﬁc treatment costs included diagnostic and imag-
ing procedures (CT, nuclear medicine, x-ray, image-guided
biopsy, etc.) as well as inpatient and outpatient oncological care
and treatments (surgery, hospitalization, chemotherapy, radia-
tion, and supportive care). All costs were estimated on the basis
of customary unit costs and practice at Hadassah Medical Center
and converted into 2011 US dollars by using the purchasing
power parity exchange rate.
Checks with other medical centers suggest that our institu-
tion’s unit cost data are comparable to those of other institutions
in our country, and so our cost data may be a reasonable
approximation to the cost of care in the health care system.
In TNM stages II-III and IV, the costs were derived from the
mean cost incurred for the treatment of patients who died within
the observation period ending December 31, 2004. At this date,
61% of the patients diagnosed at stage II-III and 77% of those
diagnosed at TNM stage IV had died. For patients diagnosed at
stage I, posthospitalization cost depends on whether the patient
was “cured” or progressed, as is described in the “ComputationalAssumptions” section later. We ignored possible heterogeneity in
patients’ preferences with respect to the treatment performed.
These stage-speciﬁc costs were applied to all patients in both
the screening cohort and the usual care arm together with base-
case assumptions on screening costs, lead time, and cure rates.
Stage-speciﬁc lifetime costs equal the discounted cost (present
value) of lung cancer treatments until death. They were calcu-
lated separately for the screening and the usual care arms.
Survival according to stage at diagnosis
Life expectancy by stage at diagnosis for patients with NSCLC was
estimated from an NCR survival check on December 31, 2006, for
all patients with NSCLC with known stage at diagnosis (n ¼ 1221).
In stages II-III and IV, where 95% of the patients have died by this
date, life expectancy was calculated as total life-years (LYs) lived
by the patients who died prior to this date divided by their
number. Life expectancy of patients diagnosed in stage I—60%,
many of them were still alive on December 31, 2006—was derived
from their estimated survival function. We ﬁtted an exponential
survival curve (years of life lived) to those who were dead by
December 31, 2006, and extrapolated it to the point of zero
probability to survive. Life expectancy is the area below the curve
(the weighted average of the years of life lived).
These stage-speciﬁc life expectancies were applied to patients
in both the screening and the usual care arms with modiﬁcations
as speciﬁed in the “Computational Assumptions” section.
Computational Assumptions
General1. The “present” is deﬁned as the time of screening, and
discounting was made to the “present” throughout.2. Costs and QALYs were discounted at a rate of 3%, beginning
from the second year in the future.
Incremental lifetime costs
To estimate the incremental costs of screening, the following
base-case assumptions were made:1. The cost of screening, including the LDCT itself and any
further diagnostic and curative treatments implied by screen-
ing ﬁndings [3,6,10–16], was calculated by using the actual unit
cost of service customary in our institution.2. For stage I patients who were “cured” (5-year disease-free
survival), the costs of ﬁve consecutive visits to an outpatient
clinic and the costs of ﬁve follow-up LDCTs were added to the
cost of treatment.3. For persons at stage I with disease progression, recurrences
occurred 2 years after diagnosis, and progressed directly to
stage IV.
Incremental life expectancy
To estimate the incremental survival beneﬁts of screening, the
following base-case assumptions were made:1. The diagnosed population consists of 75% men and 25%
women.2. For screened persons with negative ﬁndings (“well”), life
expectancy was equal to the Israel life expectancy for persons
at the age of 63 years, the mean age at detection in the cohort,
in 2004. Life expectancy of the “well” population in the usual
care arm was equal to the Israel life expectancy for persons at
the age of 65 years, the mean age at detection in patients with
NSCLC treated at our medical center.
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ability (“cure” rate) was taken as 70% for patients diagnosed at
stage I. We chose this conservative rate (the reported rate is
92% [8]) to isolate the stage-shift beneﬁts of screening. “Cured”
persons were assigned the same life expectancy as “well”
persons.4. Among those diagnosed in the usual care arm, we assumed a
70% chance of recovery for patients in stage I [21]. “Cured”
persons were assigned the same life expectancy as “well”
persons. LYs were discounted according to the lead-time
parameter, as discussed below.5. Life expectancy at stages II-III and IV was set to that estimated
from the NCR data. In the usual care arm, these ﬁgures were
modiﬁed to reﬂect the effect of lead time (see below).
Utility Weights
Individuals may perceive the value of LYs differently, depending
on the quality of life, also known as the utility of health states,
experienced in these years. QALYs take into account both
duration and quality of life determined by the progression and
severity of the illness.
Earlier studies used utility scores from two articles [19,22] to
calculate the QALYs. In the present analysis, we used a set of
scores derived by the Israel Center for Health Technology Assess-
ment [23]. These weights were based on the valuations of hypo-
thetical scenarios made by a panel of family physicians by using
the EuroQol ﬁve-dimensional questionnaire. Utility scores were
0.7086 for stage I NSCLC, 0.3412 for stage II-III NSCLC, and 0.0832
for stage IV NSCLC (and 1 for “well”). These weights are consid-
erably lower than those in Black [18] and Shrump et al. [21], who
both used weights of 0.60, 0.54, and 0.47 for these stages of
disease. The number of QALYs resulting from each of the two
strategies, to screen or not screen, is the sum of the products of
the duration of the disease for each stage multiplied by the utility
score for that stage. The duration in each stage is given in the
“Incremental life expectancy” subsection in the “Computational
Assumptions” section above.
The end point of this analysis is the cost per QALY gained by
screening. We note that because life expectancy in stages
II to IV is short, and cured persons live mostly in a “well” state,
the total number of QALYs gained is quite close to the number
of LYs gained, and cost per QALY is quite close to the cost
per LY.Dealing with Potential Biases
Lead time
The median age at detection by screening was 63 years, and the
median age at detection by symptoms was 67 years (for both the
Hadassah Medical Center patients and for the NCR). The lead
time, namely, the difference between the median ages, is 4 years.
This is a higher lead time than estimated on the basis of
tumor doubling time [4,5,16]. We set the lead time base-case
value to 2 years, and the sensitivity analysis covered the values of
0 and 4. We note that the effect of the lead time parameter is
through the timing of symptoms relative to the time of screening.
As the lead time increases, the difference in time between the
“present” and the appearance of symptoms increases, and the
effect of discounting on the present value of future costs and
beneﬁts is greater. Also, at longer lead times, the mean age at
detection by symptoms is more advanced, and the life expect-
ancy of “well” and cured persons is lower. Consequently,
with increasing lead time, the present value of both the cost
and the life expectancy of usual care is lower. With zero lead
time, there is no time gap between the diagnosis of screen- and
symptom-detected patients, and the “pure” effect of screening onstage at diagnosis, and hence on costs and life expectancy, is
revealed.
Overdiagnosis
Overdiagnosis is a major concern in cost-effectiveness studies
relating to cancer screening [19]. Analytical techniques and
assumptions regarding overdiagnosis in economic evaluations
differ dramatically. An Australian study, based on earlier autopsy
reports, set the overdiagnosis rate as 12% to 20% [13]. Some
studies [6,11,16] set the base-case overdiagnosis rate of LDCT to
zero; namely, all patients diagnosed by screening would have
been diagnosed by usual care if not screened. Another study [12]
set the combined overdiagnosis and lead time rate to three times
the incidence rate. Overdiagnosis results in unnecessary diag-
nostic and treatment procedures, which raises the cost—in
human and ﬁnancial terms—of screening. Consequently, if one
ignores the possibility of overdiagnosis, the attractiveness of
screening is overestimated.
In the present study, we combined the effect of overdiagnosis
with that of self-selection into screening, as explained below.
Self-selection into the screened population
As mentioned above, accounting for any difference in risk
stemming from varying incidence or prevalence between the
screened population and the population treated by usual care is
crucial to the analysis. On the one hand, if screening is optional
for a given group, as is the case with current LDCT screening
programs, individuals with higher than average risk (e.g., heavier
smokers) may consider screening more important than do other
members of the population (positive self-selection). The implica-
tions are similar to those of overdiagnosis; namely, if such
selection is ignored, the value of screening might be overesti-
mated. Or, put differently, a high cost per QALY might result not
from LDCT screening being unattractive but from the screened
population being relatively sicker. On the other hand, wealthier
and more educated persons may be overrepresented in the
screened population because of higher risk aversion with respect
to illness, higher demand for preventive measures, or higher
ability to pay. In this case, the screened population may prove
healthier than that treated by usual care (negative self-selection).
In such a case, the cost of screening is low, and ignoring such
selection would underestimate the value of screening. In other
words, a low cost per QALY might result not from LDCT screening
being attractive but from the screened population being relatively
healthy. Unfortunately, for the usual care population, smoking
history was not available, and a comparison of the risk distribu-
tion in the screened and the usual care populations was not
feasible.
A combined index of overdiagnosis and self-selection
Overdiagnosis and positive self-selection have different meaning
and origin; however, both result in a higher incidence of cancer in
the screened population, and it is impossible to distinguish
between their effects on the cost per QALY. We therefore created
a single index to represent overdiagnosis and self-selection,
deﬁned as the ratio of the incidence in the usual care population
to that in the screened population (denoted by k).
With no overdiagnosis and no self-selection, k ¼ 1. When k o
1, overdiagnosis and/or positive risk selection exist. The value of
0.5, for example, indicates that the incidence in the symptomatic
population is 50% less than that in the screened population.
When k 4 1, no overdiagnosis exists, but there is negative self-
selection; namely, the screened population is at lower risk than
the usual care population. When the index is 1.5, for example, the
symptomatic incidence of lung cancer is 50% more than in the
screened population.
Table 1 – Cost of diagnosing and treating non–small cell lung cancer (2011, $).
A. Selected screening, diagnostic, and surgical procedures
Procedure Cost ($)
LDCT 74
PET/CT 236
FNA 276
CT-guided lung biopsy 276
Bronchoscopy 222
Open pneumotectomy 5532
Lobectomy 3688
B. Stage-speciﬁc cost (mean  SD) by type of care
Type of care Stage I Stage II-III Stage IV
Cured Progressed
Diagnostic workup 1,810  $1,123 5,217  1,950 3,121  1,918 2,456  2,019
Hospitalization 4,302  4,739 12,452  8,228 4,436  4,093 6,721  7,472
Chemotherapy 2,477  3,572 7,457  10,336 3,299  5,740 4,903  7,371
Radiation therapy 360  815 964  2,360 6,571  6,102 4,075  5,580
Supportive care 292  469 844  1,358 191 356 817  3,364
Total 9,241  11,277 26,934  24,786 17,618  9,271 18,972  14,297
CT, computed tomography; FNA, ﬁne needle aspiration; LDCT, low-dose computed tomography; PET, positron emission tomography.
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diagnosis/positive self-selection as the base-case value; namely,
k ¼ 0.9. In the sensitivity analysis, we varied the index between
0.5 and 1.5.Sensitivity Analysis
We performed three types of sensitivity analysis. First, we
calculated the cost per QALY gained for speciﬁc values of
selected parameters of particular interest: setting the stage
distribution in usual care to two distributions found by Surveil-
lance Epidemiology and End Results (SEER) and setting the lead
time (base-case value ¼ 2) to 0 and 4. Second, we performed one-
way sensitivity analysis of all the remaining parameters (Tornado
diagram), allowing the parameters to range generally between
0.5 and 1.5 of their base-case values (for several parameters, this
range was narrowed for reasons reported below). Finally, we
performed a probabilistic sensitivity analysis. In this analysis, we
assigned the beta distribution to all probabilities, with means set
to the base-case values and SD set to 0.03. Cost variables were
assigned the gamma distribution, with mean and SD set to the
base-case value. QALYs variables were assigned the gamma
distribution, with means set to the base-case values and SD set
to the square root of half the mean. The overdiagnosis/self-
selection index (k) was assigned a uniform distribution on the
range (0.5, 1.5).Results
LDCT was negative in 750 (89.1%) and positive in 92 (10.9%)
individuals. Among the 92 patients with positive ﬁndings at
screening, 24 (25.9%) were lost to follow-up. We assumed that
the proportion of true positives in the lost to follow-up popula-
tion is similar to that in the valid positive patients (0.13). The
prevalence of NSCLC in the screened population was 1.419 per
1000 persons (0.109  0.13 ¼ 0.014; 95% conﬁdence interval 0.011–
0.018).The Cost in the LDCT Screening Arm
The cost of baseline LDCT was $74, and this was the mean cost
for 750 screened individuals with negative LDCT screening ﬁnd-
ings. The mean cost of diagnosing or ruling out lung cancer in the
92 screened individuals with positive screening ﬁndings was
$480. In “well” persons (negative or false-positive ﬁndings at
screening), the mean cost of screening together with the workup
of false-positive ﬁndings was $113 per person. Averaged across
the entire screened population (n ¼ 842), the cost of baseline
screening plus workup of positive ﬁndings was $118 per person.
This cost does not include the stage-speciﬁc treatment costs for
patients with true-positive ﬁndings.Stage-Speciﬁc Lifetime Cost of Care
Table 1A presents the unit cost of selected LDCT screening and
diagnostic surgical procedures for the workup of positive ﬁnd-
ings, as well as surgical procedures. Table 1B presents the stage-
speciﬁc costs for diagnosis, hospitalization, radiotherapy, chemo-
therapy, and palliative care in the study population. The compo-
sition of total cost varies: In stages I and IV, the main cost
components are hospitalization and chemotherapy costs; in
stage II-III, radiation cost is relatively high. The overall average
cost during initial treatment for patients with NSCLC in all stages
in the usual care arm is $17,518  $14,240. We note that the SDs
of the costs are close to the means.
These stage-speciﬁc costs are used to construct the discounted
lifetime stage-speciﬁc cost of care for the base case, which is shown
in Table 2A. These ﬁgures present the cost of treating NSCLC until
death. As is customary in economic evaluations, other “unrelated”
medical care costs are not considered. We note that the mean cost
of care in stage II-III is the highest because the stage of disease in
many of these patients progresses and thus they incur costs
associated with treatment in stage IV as well.
The discounted lifetime cost of treatment for NSCLC differs
between screening and usual care for each stage at diagnosis.
Two reasons account for these differences: lead time, which
alters the timing, and thus the present value, of NSCLC treatment
Table 2 – Base case parameter values.
Parameter’s
name
Legend Value
A. Costs (2011 $)
CostS1cure Cost of stage I cured
detected by screening
9,721
CostS1prog Cost of stage I progressed
detected by screening
27,414
CostS23 Cost of stage II–III
detected by screening
29,875
CostS4 Cost of stage IV detected
by screening
19,452
CostSfalseP Cost of false-positive
detected by screening
485
CostStrueN Cost of true-negative
detected by screening
74
CostN1cure Cost of stage I cured
detected by symptoms
8,710
CostN1prog Cost of stage I progressed
detected by symptoms
25,387
CostN23 Cost of stage II–III
detected by symptoms
27,708
CostN4 Cost of stage IV detected
by symptoms
17,883
CostNwell Cost of “well” persons 0
B. QALYs
QALYbaseline QALYs for “well” persons 15.342
QALYS1cure QALYs for stage I cured
detected by screening
13.885
QALYS1prog QALYs for stage I
progressed detected by
screening
1.46462
QALYS23 QALYs for stage II–III
detected by screening
0.421034
QALYS4 QALYs for stage IV
detected by screening
0.053248
QALYN1cure QALYs for stage I cured
detected by symptoms
13.867
QALYN1prog QALYs for stage I
progressed detected by
symptoms
3.35142238
QALYN23 QALYs for stage II–III
detected by symptoms
2.386927
QALYN4 QALYs for stage IV
detected by symptoms
2.047768
C. Probabilities
pS_P Probability of positive
result in screening
0.109
pS_TP Probability of a true-
positive result in
screening
0.130
Prevalence In the screening cohort pS_P 
pS_TP
pS_TP1 Probability of stage I in
screening
0.833
pS_TP23 Probability of stage II–III in
screening
0.083
pS_TP1_cure Probability of stage I cured
in screening
0.700
Incidence In the usual care cohort pS_P 
pS_TP 
k
Table 2 – continued
Parameter’s
name
Legend Value
pND_Stage1 Probability of stage I in
usual care
0.115
pND_Stage1_cure Probability of stage I cured
in usual care
0.700
pND_Stage23 Probability of stage II–III in
usual care
0.191
k Overdiagnosis/self-
selection parameter
0.900
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 2 2 – 9 3 1 927costs; and the cost of screening and diagnosing positive cases.
Because of stage shift with screening, the greatest difference
between the discounted lifetime costs in the two arms is seen
when patients diagnosed at all stages of disease are considered
together.
The overall mean cost of NSCLC diagnosis and care was $295
per patient in the screening cohort and $208 in the usual
care arm.
Stage-Speciﬁc Life Expectancy
Based on data from the Israel NCR and Central Bureau of
Statistics Complete Life Tables for 2002-2006, as well as the
computational assumptions described in the “Methods” section,
Table 2B presents the base-case discounted QALYs at diagnosis
according to stage at diagnosis, and the recovery status for
patients diagnosed at stage I by screening versus usual care.
The difference in discounted QALYs for the two modes of
detection originates from survival during lead time in the usual
care arm (base-case lead time is 2 years), which increases the
time to detection but decreases the discounted QALYs.
To illustrate this point, life expectancy in stage IV is 0.64 years
after diagnosis. In the screening arm, where the diagnosis is
made in the present, life expectancy is 0.64 years. In the usual
care arm, where the diagnosis is made 2 years in the future (lead
time), life expectancy in stage IV is 2.64, or 2.574 after discounting
and accounting for survival probability during lead time. Because
of the stage shift with screening, the greatest difference between
the discounted QALYs in the two arms is seen when patients
diagnosed at all stages of disease are considered together.
The discounted life expectancy in the screening arm is
15.24507 QALYs versus 15.18599 in the usual care arm.
Probabilities
The probabilities that were used in the base case are presented in
Table 2C.
Economic Evaluation of Baseline LDCT: Base-Case Scenario
The incremental cost of screening is $86.4705. Incremental
effectiveness is 0.059082 QALYs, and the cost per QALY gained
by screening is $1464.
Sensitivity Analysis
In general, the ﬁnding of a low cost per QALY gained by screening
remains quite robust across large variations of the key
parameters.
Usual care stage distribution
Using two US SEER stage I, II-III, and IV distributions (0.2, 0.39, and
0.41, and 0.143, 0.334, and 0.523, respectively) [24,25] instead of the
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tion in the relative frequency of the comparatively inexpensive
stage IV lifetime cost of care and an increase in the relative
frequency of the more costly stage II-III lifetime cost. This l
owers the cost per QALY gained by screening from $1464 to $562–
$702.
Lead time
When lead time is set to zero, meaning the detection by
symptoms occurs within 1 year of detection by screening, the
incremental cost per QALY gained is $76. Incremental cost and
QALYs are not zero in this scenario due to the different stage
distribution and cure probabilities in the two arms.
Longer lead time is associated with increased incremental
cost, because the present value of the cost of usual care
decreases. It is also associated with decreased incremental
QALYs, because, in terms of present value, the longer survival
due to increased lead time is greater than the reduction in life
expectancy with advanced age at detection. Therefore, the cost
per QALY gained increases. When lead time is 4 years, the cost
per QALY gained is $2535.
Tornado diagram
Figure 2 presents the sensitivity of the incremental cost-
effectiveness ratio (cost per QALY) to changing the values of theFig. 2 – Tornado diagram for LDCT lung cancer screening. LDCT, l
year.(remaining) parameters in a range from 50% to 150% of the base-
case value in a Tornado diagram. The maximal values for
probabilities were set to 1. For several parameters, the range
was narrowed to keep the diagram readable.
The most dramatic effect is that of the overdiagnosis/self-
selection index (k): when k ¼ 0.8, the cost per QALY reaches
$2480. When k ¼ 1.2, namely, the case of negative self-selection—
the screened cohort is healthier than the usual care population—
the cost per QALY gained is $155. When k ¼ 1, namely, neither
overdiagnosis nor self-selection exists, the cost per QALY gained
by screening is $1234.
Increased stage-speciﬁc lifetime costs in the screening arm
increase the cost per QALY. It reaches $2450 when the cost of
progressed patients diagnosed at stage I (CostS1prog) is 150% of
the base-case value. When the LDCT cost (base-case value is $74)
is halved, the cost per QALY gained is $1050. When it is 150% of
the base-case value, the cost per QALY is $2076.
Increased stage-speciﬁc lifetime costs in the usual care arm
lower the cost per QALY gained by screening. This is particularly
clear for the cost of stage IV. When this cost (CostN4) is set to
150% of the base-case value, the cost per QALY gained reaches
$224. When it is set to 50% of the base-case value, the cost per
QALY reaches $2538.
The cost of health care in Israel is considerably lower than the
cost in other Western nations, primarily due to markedly lower
salaries for health care workers. If all costs are doubled, toow-dose computed tomography; QALY, quality-adjusted life-
Fig. 3 – Acceptability curves for LDCT lung cancer screening. CE, cost-effectiveness; LDCT, low-dose computed tomography.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 2 2 – 9 3 1 929approximate the US cost level (see below), the cost per QALY is
doubled and reaches $2928.
The sensitivity analysis of the effects of changing the number
of QALYs (regardless of whether it originates from changes in
survival or in utility weights) shows that these effects are
minimal. An exception is QALYS1cure—the effectiveness in cured
persons screened-diagnosed in stage I: when this value is 10
(base-case value is 13.9), the cost per QALY increases to $3187.
When this value is 16, the cost per QALY drops to $1233.
The prevalence in the screening arm is the multiplication of
pS_P and pS_TP. The cost per QALY is quite sensitive to the
values of these probabilities, and hence to the prevalence. When
the prevalence is low, the cost per QALY gained by screening is
relatively high (when the prevalence is 0.007, the cost per QALY is
$3243). When the prevalence is 0.02, the cost per QALY gained
drops to $691.
Probabilistic sensitivity analysis
Figure 3 presents the acceptability curves of the two strategies for
a range of threshold social values of QALY (the social willingness
to pay per QALY). These are based on a Monte Carlo simulation
where 1000 samples were drawn from the parameters’ distribu-
tions described in the “Methods” section. The results suggest that
the cost per QALY gained by screening is lower than $2,000 with
probability 0.523, is lower than $10,000 with probability 0.937, is
lower than $16,000 with probability 0.973, and is lower than
$20,000 with probability 0.978.Discussion
In 2006, a systematic health technology assessment review [26]
assessed the cost-effectiveness of LDCT screening for lung cancer
as reported in one Japanese and ﬁve American studies performed
between 1994 and 2004 [6,11,12,16]. The health technology
assessment review concluded that cost-effectiveness studies
were premature at that time, given the limited data on the
clinical effectiveness of screening. Recent results of a randomizedtrial comparing LDCT and x-ray screening have now shown LDCT
to have a signiﬁcant beneﬁt in reducing lung cancer mortality [9];
thus, it is now appropriate to carefully consider the costs and
beneﬁts of screening.
Our analysis suggests that baseline LDCT screening for lung
cancer in individuals at moderate-to-high risk in Israel is asso-
ciated with a relatively low cost per QALY gained. This ﬁnding is
robust with respect to changes in the economic and epidemio-
logical parameters of the evaluation, as well as changes in
parameters reﬂecting the possible classical biases associated
with screening—lead time, overdiagnosis, and self-selection.
With 98% conﬁdence, the cost per QALY gained by screening is
below $20,000.
In this respect, our results are consistent with the conclu-
sions of earlier studies using the Early Lung Cancer Program
data set for baseline LDCT [6,16], which found a relatively low
cost per LY and cost per QALY gained for LDCT lung cancer
screening.
The cost per LY gained by screening found by Wisnivesky
et al. [16] in the analysis of LDCT screening in the United States,
however, was $3224 (2011 prices) while our result for Israel—with
a less favorable scenario for screening (10% overdiagnosis and
equal 70% cure rate of stage I in screening and in usual care)—is
$1463 per QALY. Table 3 compares the main parameters in the
two analyses. First, on comparing the cost of selected procedures
as well as the stage-speciﬁc costs, the general cost level in the
United States seems to be twice as high as the Israeli cost level.
Adjusting the cost per QALY for the cost differences raises the
cost per QALY gained in Israel to $2928. Second, our analysis is
based on the newer International Early Lung Cancer Program
protocol that evolved with cumulative screening experience.
With this protocol, we had a lower rate of false-positive results
(12% in our study vs. 23% for Wisnivesky et al. [16]). In addition,
the new protocol provides a simpliﬁed algorithm for working up
positive ﬁndings, leading to lower cost for diagnosis. Third, the
Israeli screened cohort is younger and in lower risk than
the American cohort, leading to lower costs of screening. Fourth,
the lead time, on the whole, is smaller in our study. This leads to
Table 3 – A detailed comparison between Wisnivesky et al. [16] and our study.
Assumptions and approaches in Wisnivesky et al. [16] Assumptions and approaches in current study
(base case)
Study objective Assess cost-effectiveness of a single baseline
LDCT in the ELCAP study population
Study objective Assess cost-effectiveness
of a single baseline
LDCT in a cohort of
screened individuals
End points Incremental cost per year of life saved End points Incremental cost/QALY
Screened cohort ≥60 y old, ≥10 pack-years (ELCAP) Screened cohort 450 y old, 410 pack-
years (n ¼ 571); 440 y
old, any smoking
history (n ¼ 271)
Lesions requiring follow-
up in screening
23% (ELCAP) Lesions requiring follow-
up in screening
10.9%
Lung cancer prevalence 2.7% (ELCAP) Lung cancer prevalence 1.4% (screened cohort)
Rate of overdiagnosis 0 in base case, varied in sensitivity analysis Overdiagnosis and self-
selection
0 in base case, varied as a
single index in
sensitivity analysis
Self-selection Not included in analysis
Stage distribution at
diagnosis (%)
Screening (ELCAP) Usual care
(SEER)
Stage distribution at
diagnosis (%)
Screening Usual care
(INCR)
Stage I 85 20 Stage I 83.3 11.5
Stage II 4 6 Stage II–III 8.3 19.1
Stage IIIA 7 16 Stage IV 8.3 69.4
Stage IIIB 4 17
Stage IV 0 41
Life expectancy at
diagnosis (LYs)
(NCHS, SEER) Life expectancy at
diagnosis (QALYs)
(INCR and ICTAHC)
Stage I–II curative
surgery
16.3 Stage I-cure 13.9
Stage I 4.4 Stage I-progressed 1.5
Stage II 3.5 Stage II–III 0.42
Stage IIIA 2.6 Stage IV 0.05
Stage IIIB 1.6
Stage IV 1.0
Lead time (y) Estimate based on expert opinion
and doubling time
Stage I 1.5 Stage I 2.0
Stage II 2.5 Stage II–III 2.0
Stage IIIA 3.5 Stage IV 2.0
Stage IIIB 4.0
Stage IV 4.5
Cost assumptions (US $
2011 prices)
(Data from NY Presbyterian Hospital) Cost assumptions (US $
2011 prices)
(Data from Hadassah-
Hebrew University
Medical Center)
LDCT 165 LDCT 74
HRCT 300 PET/CT 236
FNA 500 FNA 276
Treatment of NSCLC Cost (US $) Treatment of NSCLC Cost (US $)
Stage I 25,929 Stage I 15,513
Stage II 30,075 Stage II–III 17,619
Stage IIIA 41,022 Stage IV 18,683
Stage IIIB 42,183
Stage IV 33,411
ELCAP, Early Lung Cancer Program; FNA, ﬁne needle aspiration; HRCT, high‐resolution computed tomography; ICTAHC, Israeli Center for
Technology Assessment in Health Care; INCR, Israeli National Cancer Registry; LDCT, low-dose computed tomography; LYs, life-years; NCHS,
National Center for Health Statistics; NSCLC, non–small cell lung cancer; PET, positron emission tomography; SEER, Surveillance Epidemiology
and End Results; QALYs, quality-adjusted life-years.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 2 2 – 9 3 1930a higher present value of cost of usual care and hence to lower
incremental cost of screening.
While the results of our study suggest that LDCT screening
is—with high probability—cost-effective in Israel, threelimitations of the study should be noticed. First, both the
screened and the usual care cohorts are relatively small, leading
to high uncertainty in the parameters of the model. We tried to
alleviate this concern by conducting an extensive sensitivity
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 2 2 – 9 3 1 931analysis. Second, there was a large proportion of patients in the
Israeli NCR database for whom stage at diagnosis was unknown,
and in our study population, a quarter of people with positive
ﬁndings at screening were lost to follow-up. We had no choice
but to assume that these missing values were randomly deter-
mined. Third, we used our institution’s unit cost and medical
care protocols. We conducted checks with other medical centers
that suggested that our institution’s mean unit cost data are
comparable to those of other institutions in our country, and we
do not believe that this is a serious limitation.
In conclusion, our analysis suggests that LDCT lung cancer
screening in Israel may be associated with a relatively low cost
per QALYs gained by screening, and may deserve inclusion in the
public list of health services. Further research should be con-
ducted, however, to conﬁrm these ﬁndings with more recent,
larger, and more reliable data sets, and to expand the analysis to
include follow-up screenings. Such results will inform policy-
makers and will contribute to policy decisions regarding the
allocation of health care resources to LDCT screening.
Source of ﬁnancial support: The study was supported by
grants from the Israeli Cancer Society and the Joint Fund of the
Faculty of Medicine of the Hebrew University-Hadassah School of
Medicine.
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